Guangzhou Pharmaceucal Company Limited   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Guangzhou China (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2009
NCT01189656
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Jiangsu Famous Medical Technology Co., Ltd. | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenomatous Polyps (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Cerebral Hemorrhage (Phase 4)

Diabetic Nephropathies (Phase 1)

Diarrhea (Phase 4)

Hemorrhage (Phase 4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Intracranial Hemorrhage, Hypertensive (Phase 4)

Kidney Diseases (Phase 1)

Lung Neoplasms (Phase 4)

Neoplasms (Phase 4)

Recurrence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 17